RE
RepliCel Life Sciences Inc.
REPCF · OTC
$0.00 +0.00% (+$0.00)
Market Cap $10.4K
P/E Ratio 0.00x
Div. Yield -
ROE -
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0001
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REPCF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap EV/EBITDA 2.10x
P/S 0.02x
P/E 0.00x
Growth
20 /100
Declining Rev. growth 0.03%
FCF growth N/A
Book val. growth N/A
Profitability
54 /100
Moderate FCF margin 25.56%
Op. margin 102.80%
Gross margin 16.67%
Quality
43 /100
Average ROA 9,551.74%
Asset turnover 6.56x
ROIC 71.76%
Debt
54 /100
Moderate Int. coverage 9.37x
Net debt/EBITDA 2.08x
Current ratio 0.02x
Stability
53 /100
Moderate Profitable years 0
EPS volatility 192.82%
Beta 0.56x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REPCF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew Schutte
Employees
1
Headquarters
Vancouver